Struggling with the complexities of LR-MDS patient care?

Learn how to navigate the nuanced decision-making process regarding dose titration and adverse event management in our upcoming webinar [PRIME]( [Moving the Needle: Adopting New Evidence Into the Lower-Risk Myelodysplastic Syndrome Treatment Paradigm]( [REGISTER NOW!]( [Event Details:]( [Tuesday, Jun 18, 2024 at 5:00 PM Eastern (2:00 PM Pacific)]( [1.0 CME/CE | Live Webinar]( While the frontline treatment landscape expands for lower-risk myelodysplastic syndrome (LR-MDS), providers are faced with new opportunities and challenges to individualizing care. Join leading LR-MDS experts in this research-informed webinar, which will divulge real-world challenges to integrating novel LR-MDS therapies and mitigating treatment-related adverse events identified through a recent hematology/oncology provider survey. The expert faculty will then take the audience through complex clinical cases, sharing real-world perspectives with various "what if" scenarios to explore key nuances of decision-making regarding dose titration and adverse event management. Wrapping up with a live question and answer session, this webinar is designed to equip you with evidence-based strategies to individualize frontline treatment plans for LR-MDS patients. Expert Faculty: Rami Komrokji, MD Speaker Professor of Medicine and Oncologic Sciences University of South Florida College of Medicine Vice Chair, Malignant Hematology Department Moffitt Cancer Center Tampa, FL Mikkael A. Sekeres, MD Speaker Professor of Medicine Chief, Division of Hematology Sylvester Cancer Center University of Miami Miami, FL [REGISTER NOW!]( [Prime Education] PRIME Education, LLC 114 5th Ave, 14th Floor New York, NY 10011 (954) 718-6055 | [Contact us]( PRIME is a multi-disciplinary accredited provider of continuing medical education. [Unsubscribe from future emails](lst=NL_Prime_Live_Events) | [Contact us]( | [COVID-19 Resource Center](